chronic atrophic gastritis
Conditions
Interventions
treatment group:Moluodan, Moluodan analogue and folic acid analogue
High dose control group:Moluodan, Moluodan and folic acid analogue
Positive drug control group:Moluodan analogue, Moluodan analogue and folic acid
Combined control group:Moluodan, Moluodan analogue and folic acid
Sponsors
Renji Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18-70 years old, male or female; 2. Patients who meet the diagnostic criteria of Western medicine for chronic atrophic gastritis with moderate to severe atrophy and/or mild dysplasia, moderate to severe intestinal metaplasia, and negative for Helicobacter pylori (at least one of C13 or C14 breath test is required); 3. 2 experts from pathology department should diagnose the patients (pathological reading), and the 2 experts can agree on it; 4. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined with peptic ulcer, moderate or severe dysplasia of gastric mucosa or pathological diagnosis of suspected malignancy; 2. With a history of serious digestive system diseases or abdominal operation; 3. Women in pregnancy and lactation; 4. Combined with serious heart, lung, hematopoietic, malignant tumor and other primary diseases, patients with severe diabetes, chronic liver and kidney dysfunction, including liver function damage ALT > 1.5 times the upper limit of normal value, or renal function damage serum creatinine (Cr) > 1.5 times the upper limit of normal value; 5. Platelet count below 0.75 times the lower limit of normal value; 6. Patients with disabilities prescribed by law (blindness, deafness, dumb, mental retardation, mental disorder, physical disability); 7. Patients with a history of alcoholism; 8. Allergic constitution or history of allergy to multiple drugs (more than two or known components in the drug); 9. Participated in the clinical trials of other drugs within the past 4 weeks; 10. According to the researcher's judgment, it is easy to cause loss of follow-up, or other reasons that should not be selected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biopsy pathology results; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic diagnosis;Pepsinogen and Gastrin 17;HP detection;stomach age; | — |
Countries
China
Contacts
Public ContactJingyuan Fang
Renji Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed